Key data on economic impact of Bronchiolitis Obliterans Syndrome (BOS) presented at ISHLT 2021
Key data on economic impact of Bronchiolitis Obliterans Syndrome (BOS) presented at ISHLT 2021
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Recent announcements, achievements, and development milestones from PARI's pharmaceutical partners utilizing eFlow® Technology.
Key data on economic impact of Bronchiolitis Obliterans Syndrome (BOS) presented at ISHLT 2021
LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)
Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial
Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease
Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin